SCHEMBL537493

SCHEMBL537493

Cc1ccc(S(=O)(=O)O)cc1CC1CO1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
CA1 P00915 3/20 0.37
CA2 P00918 3/20 0.37
CA12 O43570 2/20 0.37
CA7 P43166 2/20 0.37
CA14 Q9ULX7 2/20 0.37
ALDH1A1 P00352 5/20 0.36
PKM P14618 3/20 0.36
LMNA P02545 2/20 0.36
GAA P10253 2/20 0.36
MAPT P10636 1/20 0.36
SNCA P37840 1/20 0.35
HSD17B10 Q99714 1/20 0.34
HTT P42858 1/20 0.33
YAP1 P46937 1/20 0.33
TEAD4 Q15561 1/20 0.33
PRMT5 O14744 1/20 0.33
WDR77 Q9BQA1 1/20 0.33
RXRA P19793 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3673653 1.00 KMT2A (0.38) KMT2AMEN1CA1CA2CA12
SCHEMBL5153698 0.91 CA1 (0.34) KMT2AMEN1CA1CA2CA12
SCHEMBL2364146 0.89 USP2 (0.41) CA1CA2CA12CA7CA14
SCHEMBL26641101 0.85 SNCA (0.36) CA1CA2CA12CA7CA14
SCHEMBL2484470 0.84 ATM (0.45) KMT2AALDH1A1PKMLMNAGAA
SCHEMBL27216045 0.83 CA1 (0.34) KMT2AMEN1CA1CA2CA12
SCHEMBL15232290 0.82 CA1 (0.32) KMT2AMEN1CA1CA2CA12
SCHEMBL1888652 0.82 CA2 (0.39) KMT2AMEN1CA1CA2CA12
SCHEMBL2484523 0.80 PIK3CD (0.36) KMT2AMEN1ALDH1A1
SCHEMBL7286938 0.80 LMNA (0.51) KMT2AMEN1CA2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3124513-B1 GRAFT POLYMER AND METHOD FOR PRODUCING SAME NITTO BOSEKI CO LTD (JP) 2020-04-22 EP claimed
EP-0930307-B1 PROCESS FOR THE PREPARATION OF GLYCIDYL ETHERS DAISO CO LTD (JP) 2002-12-04 EP claimed
EP-0930291-B1 PROCESS FOR THE PREPARATION OF 3-AMINO-2-HYDROXY-1-PROPYL ETHERS DAISO CO LTD (JP) 2002-08-14 EP claimed
US-8153651-B2 Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same EVOTEC AG (DE) 2012-04-10 US disclosed
EP-2215054-B8 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME EVOTEC AG (DE) 2012-02-08 EP disclosed
US-20110021514-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME RENOVIS, INC. (US) 2011-01-27 US disclosed
EP-2215054-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME Renovis, Inc. (US) 2010-08-11 EP disclosed
EP-2178886-A1 MACROCYCLIC INDOLE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C INFECTIONS Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) 2010-04-28 EP disclosed
EP-2178885-A1 MACROCYCLIC INDOLE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C INFECTIONS Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) 2010-04-28 EP disclosed
WO-2009064449-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME RENOVIS, INC. (US) 2009-05-22 WO disclosed
WO-2009010783-A1 MACROCYCLIC INDOLE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C INFECTIONS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2009-01-22 WO disclosed
WO-2009010785-A1 MACROCYCLIC INDOLE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C INFECTIONS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2009-01-22 WO disclosed
EP-1802597-A1 ASYMMETRIC SYNTHESIS OF SUBSTITUTED DIHYDROBENZOFURANS Wyeth a Corporation of the State of Delaware (US) 2007-07-04 EP disclosed
WO-2006047228-A1 ASYMMETRIC SYNTHESIS OF SUBSTITUTED DIHYDROBENZOFURANS WYETH (US) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021514-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME TRPV1, TRPA1, TRPV2 KMT2A 4331/4885MEN1 4561/4885CA1 876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.